Skip to main content
SpringerLink
Log in

Ovarian Cancer Biomarkers: Moving Forward in Early Detection

  • Chapter
  • First Online:
Tumor Microenvironment

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1219))

Abstract

Ovarian cancer is a silent cancer which rate survival mainly relays in early stage detection. The discovery of reliable ovarian cancer biomarkers plays a crucial role in the disease management and strongly impact in patient’s prognosis and survival. Although having many limitations CA125 is a classical ovarian cancer biomarker, but current research using proteomic or metabolomic methodologies struggles to find alternative biomarkers, using non-invasive our relatively non-invasive sources such as urine, serum, plasma, tissue, ascites or exosomes. Metabolism and metabolites are key players in cancer biology and its importance in biomarkers discovery cannot be neglected. In this chapter we overview the state of art and the challenges facing the use and discovery of biomarkers and focus on ovarian cancer early detection.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ApoA-1:

Apolipoprotein A-1

AS:

Advanced Stage

CA125:

Cancer Antigen 125

COL3A1:

Collagen alpha-1 (III)

EMILIN2:

Elastin microfibril interfacer 2

EphA8:

Ephrin receptor A8

ESD:

Early Stage Disease

FDA:

Food and Drug Administration

FGA:

Fibrinogen alpha

FGB NT:

Fibrinogen beta NT

FSH:

Follicle-Stimulating Hormone

FTL:

Ferritin light chain

HE4:

Human Epididymis protein 4

Hp:

Haptoglobin

HSP27:

Heat Shock Protein 27

IGF-2:

Insulin-like Growth Factor 2

IR-2α:

Interleukin-2 Receptor α

ITIH4:

Inter-α-Trypsin Inhibitor heavy chain H4

NAGK:

N-acetyl-D-glucosamine kinase

NM23-H1:

Nucleoside diphosphate kinase A

PA28:

Reg-alpha fragment

PEBP1:

Phosphatidylethanolamine Binding Protein 1

PP1:

Protein phosphatase-1

Prx-II:

Peroxiredoxin II

PSMA6:

Proteasome alpha-6

SCEH:

Mitochondrial short-chain enoyl-CoA hydratase

TTR:

Transthyretin

TVUS:

Transvaginal Ultrasonography

VWF:

von Willebrand factor

References

  • Ahmed N, Barker G, Oliva KT, Hoffmann P, Riley C, Reeve S, Smith AI, Kemp BE, Quinn MA, Rice GE (2004) Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer 91:129–140

    Article  PubMed  PubMed Central  Google Scholar 

  • Ahmed N, Oliva KT, Barker G, Hoffmann P, Reeve S, Smith IA, Quinn MA, Rice GE (2005) Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics 5:4625–4636

    Article  PubMed  Google Scholar 

  • Akinyemiju T, Moore JX, Judd SE, Pisu M, Goodman M, Howard VJ, Long L, Safford M, Gilchrist SC, Cushman M (2018) Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality. Oncotarget 9:16099–16109

    Article  PubMed  PubMed Central  Google Scholar 

  • An HJ, Kim DS, Park YK, Kim SK, Choi YP, Kang S, Ding B, Cho NH (2006) Comparative proteomics of ovarian epithelial tumors. J Proteome Res 5:1082–1090

    Article  PubMed  Google Scholar 

  • Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1:845–867

    Article  PubMed  Google Scholar 

  • Anderson NS, Bermudez Y, Badgwell D, Chen R, Nicosia SV, Bast RC Jr, Kruk PA (2009) Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol 112(1):60–67

    Article  PubMed  Google Scholar 

  • Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC Jr (2007) Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol 106(3):490–497

    Article  PubMed  PubMed Central  Google Scholar 

  • Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB (1998) CA125: the past and the future. Int J Biol Markers 13:179–187

    Article  PubMed  Google Scholar 

  • Bergen HR 3rd, Vasmatzis G, Cliby WA, Johnson KL, Oberg AL, Muddiman DC (2003) Discovery of ovarian cancer biomarkers in serum using NanoLC electrospray ionization TOF and FT-ICR mass spectrometry. Dis Markers 19:239–249

    Article  PubMed  Google Scholar 

  • Bharti SK, Wildes F, Hung CF, Wu TC, Bhujwalla ZM, Penet MF (2017) Metabolomic characterization of experimental ovarian cancer ascitic fluid. Metabolomics 13:113

    Article  PubMed  PubMed Central  Google Scholar 

  • Bosco C, Wulaningsih W, Melvin J, Santaolalla A, De Piano M, Arthur R, Van Hemelrijck M (2015) Metabolic serum biomarkers for the prediction of cancer: a follow-up of the studies conducted in the Swedish AMORIS study. ecancer 9:555

    Article  Google Scholar 

  • Bruntz RC, Belshoff AC, Zhang Y, Macedo JKA, Higashi RM, Lane AN, Fan TW (2019) Inhibition of anaplerotic glutaminolysis underlies selenite toxicity in human lung cancer. Proteomics 12:e1800486

    Article  Google Scholar 

  • Chambers AF, Vanderhyden BC (2006) Ovarian cancer biomarkers in urine. Clin Cancer Res 12(2):323–327

    Article  PubMed  Google Scholar 

  • Cohen JG, White M, Cruz A, Farias-Eisner R (2014) In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem 5(3):286–300

    Article  PubMed  PubMed Central  Google Scholar 

  • Coleman R, Herzog T, Chan D, Munroe D, Pappas T, Smith A, Zhang Z, Wolf J (2016) Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. Am J Obstet Gynecol 215:82.e1–82.e11

    Article  PubMed  Google Scholar 

  • Collins RRJ, Patel K, Putnam WC, Kapur P, Rakheja D (2017) Oncometabolites: a new paradigm for oncology, metabolism, and the clinical laboratory. Clin Chem 63(12):1812–1820

    Article  PubMed  Google Scholar 

  • Dando I, Pozza ID, Ambrosini G, Torrens-Mas M, Butera G, Mullappilly N, Pacchiana R, Palmieri M, Donadelli M (2019) Oncometabolites in cancer aggressiveness and tumour repopulation. Biol Rev 94(4). https://doi.org/10.1111/brv.12513

  • Diavatis S, Papanikolaou A (2016) Level of HE4 is correlated with diagnosis of struma ovarii: a case report. Am J Case Rep 17:459–461

    Article  PubMed  PubMed Central  Google Scholar 

  • Drenberg CD, Saunders BO, Wilbanks GD, Chen R, Nicosia RF, Kruk PA, Nicosia SV (2010) Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer. Gynecol Oncol 117(1):117–124

    Article  PubMed  Google Scholar 

  • Elzek MA, Rodland KD (2015) Proteomics of ovarian cancer: functional insights and clinical applications. Cancer Metastasis Rev 34:83–96

    Article  PubMed  PubMed Central  Google Scholar 

  • Feng L, Dong Z, Tao D, Zhang Y, Liu Z (2018) The acidic tumor microenvironment: a target for smart cancer nano-theranostics. Natl Sci Rev 5(2):269–286

    Article  Google Scholar 

  • Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403

    Article  PubMed  Google Scholar 

  • Fernandes C, Suares D, Yergeri MC (2018) Tumor microenvironment targeted nanotherapy. Front Pharmacol 9:1230

    Article  PubMed  PubMed Central  Google Scholar 

  • Gobbo J, Marcion G, Cordonnier M, Dias AMM, Pernet N, Hammann A, Richaud S, Mjahed H, Isambert N, Clausse V, Rébé C, Bertaut A, Goussot V, Lirussi F, Ghiringhelli F, de Thonel A, Fumoleau P, Seigneuric R, Garrido C (2016) Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer. J Natl Cancer Inst 108(3).:djv330

    Google Scholar 

  • Goo YA, Goodlett DR (2010) Advances in proteomic prostate cancer biomarker discovery. J Proteome 73:1839–1850

    Article  Google Scholar 

  • Grayson K, Gregory E, Khan G, Guinn B-A (2019) Urine biomarkers for the early detection of ovarian cancer – are we there yet? Biomark Cancer 11:1179299X19830977

    Google Scholar 

  • Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeillinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF (2017) Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers. PLoS One 12(12):e0189641

    Article  PubMed  PubMed Central  Google Scholar 

  • Guo L, Zhou B, Liu Z, Xu Y, Lu H, Xia M, Guo E, Shan W, Chen G, Wang C (2016) Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling. Tumour Biol 37(8):11007–11015

    Article  PubMed  Google Scholar 

  • Helleman J, van der Vlies D, Jansen MP, Luider TM, van der Burg ME, Stoter G, Berns EM (2008) Serum proteomic patterns for ovarian cancer monitoring. Int J Gynecol Cancer 18:985–995

    Article  PubMed  Google Scholar 

  • Horiuchi A, Itoh K, Shimizu M, Nakai I, Yamazaki T, Kimura K, Suzuki A, Shiozawa I, Ueda N, Konishi I (2003) Towards understanding the natural history of ovarian carcinoma development: a clinicopathologic approach. Gynecol Oncol 88:309–317

    Article  PubMed  Google Scholar 

  • Huber V, Camisaschi C, Berzi A, Ferro S, Lugini L, Triulzi T, Tuccitto A, Tagliabue E, Castelli C, Rivoltini L (2017) Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation. Semin Cancer Biol 43:74–89

    Article  PubMed  Google Scholar 

  • Hurteau JA, Woolas RP, Jacobs IJ, Oram DC, Kurman CC, Rubin LA, Nelson DL, Berchuck A, Bast RC Jr, Mills GB (1995) Soluble interleukin-2 receptor α is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer 76:1615–1620

    Article  PubMed  Google Scholar 

  • Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, Hartley JL, Nickson JA, Rayner SJ, Johnston C, Dieplinger B, Hubalek M, Wilkinson N, Perren TJ, Kehoe S, Hall GD, Daxenbichler G, Dieplinger H, Selby PJ, Banks RE (2007) Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res 13:7370–7379

    Article  PubMed  Google Scholar 

  • Jiang T, Lin Y, Yin H, Wang S, Sun Q, Zhang P, Bi W (2015) Correlation analysis of urine metabolites and clinical staging in patients with ovarian cancer. Int J Clin Exp Med 8(10):18165–18171

    PubMed  PubMed Central  Google Scholar 

  • Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, Weiss RH (2009) Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 8:558–570

    Article  PubMed  PubMed Central  Google Scholar 

  • Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R (2005) Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5:4589–4596

    Article  PubMed  Google Scholar 

  • Krell D, Battistino FS, Benafif S, Ganegoda L, Hall M, Rustin GJS (2017) Audit of CA125 follow-up after first-line therapy for ovarian cancer. Int J Gynecol Cancer 27(6):1118–1122

    Article  PubMed  PubMed Central  Google Scholar 

  • Kutova OM, Guryev EL, Sokolova EA, Alzeibak R, Balalaeva IV (2019) Cancers (Basel) 11(1):68

    Article  PubMed  Google Scholar 

  • Lambe M, Wigertz A, Garmo H, Walldius G, Jungner I, Hammar N (2011) Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control 22(8):1163–1171

    Article  PubMed  Google Scholar 

  • Lemaire R, Menguellet SA, Stauber J, Marchaudon V, Lucot JP, Collinet P, Farine MO, Vinatier D, Day R, Ducoroy P, Salzet M, Fournier I (2007) Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. J Proteome Res 6:4127–4134

    Article  PubMed  Google Scholar 

  • Li XQ, Zhang SL, Cai Z, Zhou Y, Ye TM, Chiu JF (2009a) Proteomic identification of tumor-associated protein in ovarian serous cystadenocarcinoma. Cancer Lett 275:109–116

    Article  PubMed  Google Scholar 

  • Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB, Morin PJ (2009b) Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer 9:244

    Article  PubMed  PubMed Central  Google Scholar 

  • Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, Jiang SW (2009c) HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 9(6):555–566

    Article  PubMed  PubMed Central  Google Scholar 

  • Lin J, Qin J, Li X, Dong P, Yin B (2012) Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and meta-analysis. Asian Pac. J Cancer Prev 13(11):5427–5432

    Google Scholar 

  • Liu X, Xu Y, Jin Q, Wang W, Zhang S, Wang X, Zhang Y, Xu X, Huang J (2016) EphA8 is a prognostic marker for epithelial ovarian cancer. Oncotarget 7(15):20801–20809

    Article  PubMed  PubMed Central  Google Scholar 

  • Lopes-Coelho F, Gouveia-Fernandes S, Gonçalves LG, Nunes C, Faustino I, Silva F, Félix A, Pereira SA, Serpa J (2016) HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC). Tumour Biol 37(4):4813–4829

    Article  PubMed  Google Scholar 

  • Melvin JC, Seth D, Holmberg L, Garmo H, Hammar N, Jungner I, Walldius G, Lambe M, Wigertz A, Van Hemelrijck M (2012) Lipid profiles and risk of breast and ovarian cancer in the Swedish AMORIS study. Cancer Epidemiol Biomark Prev 21(8):1381–1384

    Article  Google Scholar 

  • Mills GB, May C, McGill M, Roifman CM, Mellors A (1988) A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res 48(5):1066–1071

    PubMed  Google Scholar 

  • Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW (2001) Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 93:1458–1464

    Article  PubMed  Google Scholar 

  • Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, Yue L, Bray-Ward P, Ward DC (2005) Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 102:7677–7682

    Article  PubMed  PubMed Central  Google Scholar 

  • Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, Tikhonova OV, Goufman EI, Zgoda VG, Taranets IN, Makarov OV, Archakov AI (2005) Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 5:3790–3797

    Article  PubMed  Google Scholar 

  • Moss EL, Hollingworth J, Reynolds TM (2005) The role of CA125 in clinical practice. J Clin Pathol 58:308–312

    Article  PubMed  PubMed Central  Google Scholar 

  • Muthu M, Nordström A (2019) Current status and future prospects of clinically exploiting cancer-specific metabolism – why is tumor metabolism not more extensively translated into clinical targets and biomarkers? Int J Mol Sci 20(6):1385

    Article  PubMed  PubMed Central  Google Scholar 

  • Nunes SC, Ramos C, Lopes-Coelho F, Sequeira CO, Silva F, Gouveia-Fernandes S, Rodrigues A, Guimarães A, Silveira M, Abreu S, Santo VE, Brito C, Félix A, Pereira SA, Serpa J (2018) Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity. Sci Rep 8(1):9513

    Article  PubMed  PubMed Central  Google Scholar 

  • Ogiwara H, Takahashi K, Sasaki M, Kuroda T, Yoshida H, Watanabe R, Maruyama A, Makinoshima H, Chiwaki F, Sasaki H, Kato T, Okamoto A, Kohno T (2019) Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers. Cancer Cell 35(2):177–190.e8

    Article  PubMed  Google Scholar 

  • Patriotis C, Maruvada P, Srivastav S (2017) Molecular detection and diagnosis of Cancer. In: Colemann WB, Tsongalis GJ (eds) The molecular basis of human cancer, 2nd edn. Springer, New York

    Google Scholar 

  • Petri AL, Simonsen AH, Yip TT, Hogdall E, Fung ET, Lundvall L, Hogdall C (2009) Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet Gynecol Scand 88:18–26

    Article  PubMed  Google Scholar 

  • Plewa S, Horała A, Dereziński P, Nowak-Markwitz E, Matysiak J, Kokot ZJ (2019) Wide spectrum targeted metabolomics identifies potential ovarian cancer biomarkers. Life Sci 222:235–244

    Article  PubMed  Google Scholar 

  • Radpour R, Forouharkhou F (2018) Single-cell analysis of tumors: creating new value for molecular biomarker discovery of cancer stem cells and tumor-infiltrating immune cells. World J Stem Cells 10(11):160–171

    Article  PubMed  PubMed Central  Google Scholar 

  • Rei M, Gonçalves-Sousa N, Lança T, Thompson RG, Mensurado S, Balkwill FR, Kulbe H, Pennington DJ, Silva-Santos B (2014) Murine CD27(−) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc Natl Acad Sci U S A 111(34):E3562–E3570

    Article  PubMed  PubMed Central  Google Scholar 

  • Russo F, Lastoria S, Svanera G, Capobianco G, de Chiara A, di Francia R, Squame E, de Martinis F, Pinto A (2007) Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin’s lymphoma. Leukemia Lymphoma 48(4):723–730

    Article  PubMed  Google Scholar 

  • Scholler N, Urban (2007) CA125 in ovarian cancer. Biomark Med 1(4):513–523

    Article  PubMed  Google Scholar 

  • Scholler N, Gross JA, Garvik B, Wells L, Liu Y, Loch CM, Ramirez AB, McIntosh MW, Lampe PD, Urban N (2008) Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery. J Transl Med 6:41

    Article  PubMed  PubMed Central  Google Scholar 

  • Shirodkar SP, Lokeshwar VB (2009) Potential new urinary markers in the early detection of bladder cancer. Curr Opin Urol 19:488–493

    Article  PubMed  PubMed Central  Google Scholar 

  • Slupsky CM, Steed H, Wells TH, Dabbs K, Schepansky A, Capstick V, Faught W, Sawyer MB (2010) Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res 16(23):5835–5841

    Article  PubMed  Google Scholar 

  • Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys EC Jr, LaPolla JP, Arango H, Hoffman MS, Martino M, Wakeley K, Griffin D, Blanco RW, Cantor AB, Xiao YJ, Krischer JP (2004) Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomark Prev 13(7):1185–1191

    Article  Google Scholar 

  • Tanasova M, Begoyan VV, Weselinski LJ (2018) Targeting sugar uptake and metabolism for cancer identification and therapy: an overview. Curr Top Med Chem 18:467–483

    Article  PubMed  Google Scholar 

  • Wang M-L, Huang O, Yang T-X (2009) IgE myeloma with elevated level of serum CA125. J Zhejiang Univ Sci B 10(7):559–562

    Article  PubMed  PubMed Central  Google Scholar 

  • Wang J, Gao J, Yao H, Wu Z, Wang M, Qi J (2014) Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis. Tumour Biol 35(6):6127–6138

    Article  PubMed  Google Scholar 

  • Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC Jr (1993) Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 85(21):1748–1751

    Article  PubMed  Google Scholar 

  • Yang LV (2017) Tumor microenvironment and metabolism. Int J Mol Sci 18(12):2729

    Article  PubMed  PubMed Central  Google Scholar 

  • Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT, Nagrath D (2014) Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol 10:728

    Article  PubMed  PubMed Central  Google Scholar 

  • Yang C, Kim HS, Song G, Lim W (2019) The potential role of exosomes derived from ovarian cancer cells for diagnostic and therapeutic approaches. J Cell Physiol:1–11

    Google Scholar 

  • Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, Horick NK, Licklider LJ, Schorge JO, Berkowitz RS, Mok SC (2003) Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 9:2904–2911

    PubMed  Google Scholar 

  • Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW (2006) Proteomic-based discovery and characterization of glycosylated eosinophil-derived-neurotoxin and C-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 12:432–441

    Article  PubMed  Google Scholar 

  • Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW (2004) Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64:5882–5890

    Article  PubMed  Google Scholar 

  • Zhang B, Barekati Z, Kohler C, Radpour R, Asadollahi R, Holzgreve W, Zhong XY (2010) Proteomics and biomarkers for ovarian cancer diagnosis. Ann Clin Lab Sci 40(3):218–225

    PubMed  Google Scholar 

  • Zhang B, Cai FF, Zhong XY (2011) An overview of biomarkers for the ovarian cancer diagnosis. Eur J Obstet Gyn R B 158(2):119–123

    Article  Google Scholar 

  • Zhang X, Liu Y, Kim YJ, Mac J, Zhuang R, Wang P (2017) Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment. RSC Adv 7:19685–19693

    Article  PubMed  Google Scholar 

  • Zhao S, Yumei M, Xianghua H (2015) Trefoil factor 1 elevates the malignant phenotype of mucinous ovarian cancer cell through Wnt/β-catenin signaling. Int J Clin Exp Pathol 8(9):10412–10419

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. IBB – Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal

    Vasco D. B. Bonifácio

Authors
  1. Vasco D. B. Bonifácio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vasco D. B. Bonifácio .

Editor information

Editors and Affiliations

  1. CEDOC, Chronic Diseases Research Centre, NOVA Medical School | Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisbon, Portugal

    Jacinta Serpa

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bonifácio, V.D.B. (2020). Ovarian Cancer Biomarkers: Moving Forward in Early Detection. In: Serpa, J. (eds) Tumor Microenvironment . Advances in Experimental Medicine and Biology, vol 1219. Springer, Cham. https://doi.org/10.1007/978-3-030-34025-4_18

Download citation

Publish with us

Policies and ethics

Search

Navigation